Cite
HARVARD Citation
Kowanetz, M. et al. (n.d.). Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A. Journal for immunotherapy of cancer. p. . [Online].